Alnylam Pharmaceuticals

Moderna has settled patent infringement lawsuits filed by Alnylam Pharmaceuticals over alleged misuse of lipid nanoparticle technology in COVID-19 vaccines.

Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.

Biotech leaders John Maraganore and Clive Meanwell have launched Corsera Health with the ambitious goal of creating a world without cardiovascular disease.

Zilebesiran, developed by Alnylam Pharmaceuticals and Roche, targets angiotensinogen in the renin-angiotensin-aldosterone system and offers biannual dosing for hypertension management.

The U.S. District Court for the District of Delaware entered a final judgment on July 30, 2025, ruling that Pfizer's COVID-19 vaccine did not infringe any of Alnylam's patents covering nanoparticle technology.

The FDA has approved an updated label for Novartis' Leqvio (inclisiran) allowing its use as monotherapy alongside diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia.

The U.S. Court of Appeals for the Federal Circuit affirmed a district court ruling in favor of Moderna, rejecting Alnylam Pharmaceuticals' patent infringement claims over mRNA-based COVID-19 vaccine technology.

DelveInsight's 2025 pipeline analysis reveals over 20 active companies developing more than 20 pipeline drugs for Huntington's disease, including gene-targeting and disease-modifying therapies.

Scientists at the University of Nottingham have developed a cryogenic mass spectrometry approach that reveals the precise structure and molecular orientation within lipid nanoparticles used in RNA therapeutics.

• Comprehensive analysis of 700+ pharmaceutical and biotechnology partnering deals with disclosed royalty rates from 2010-2025 has been published by ResearchAndMarkets.com. • The report provides unprecedented access to actual contract documents submitted to the SEC, offering detailed insights into royalty rate structures and their integration with other financial terms. • Key industry players including AbbVie, Pfizer, Novartis, and Bristol-Myers Squibb are featured among the 50+ companies actively disclosing royalty rates in their partnership agreements.